M&A and equity raisings

6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

US deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

76 deals · US$92bndisclosed · Pharma · Clear

Columns
M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Oct 2026 mAbxience –FreseniusAcquisitionCompleted1,946.9Biotech+1 Lazard (buy-side)
Oct 2026 HCXT-2001 (investigational oral IL-23R inhibitor) PepStar TherapeuticsGileadAsset saleAnnounced–Pharma+1 Lazard
Oct 2026 Orbus Therapeutics –US WorldMedsAcquisitionCompleted–Pharma+2 Lazard
Sep 2026 Royalty participation rights in U.S. net sales of tavapadon Bain CapitalDRI Healthcare TrustAsset saleAnnounced316.0Specialty finance and leasing+2 Cravath, Swaine & Moore (buy-side)
Sep 2026 Stivarga (regorafenib) Bayer AGGrünenthalAsset saleAnnounced432.6Pharma+1 Freshfields (buy-side)
Sep 2026 portfolio of 20 mature medicines and three manufacturing sites SanofiCheplapharmAsset saleAnnounced–Pharma+1 Freshfields (sell-side)Latham & Watkins (buy-side)
Aug 2026 TYRVAYA (varenicline solution) nasal spray 0.03 mg ViatrisHarrowAsset saleAnnounced30.0Pharma+1 Cravath, Swaine & Moore (sell-side)
Aug 2026 Lantheus Holdings –Curium US HoldingsAcquisitionAnnounced8,000.0Radiopharmaceuticals+1 Morgan Stanley (sell-side)BofA Securities (sell-side)Solomon Partners (sell-side)Covington & Burling (sell-side)Ropes & Gray (sell-side)Jefferies (buy-side)J.P. Morgan (buy-side)PJT Partners (buy-side)Kirkland & Ellis (buy-side)Arnold & Porter (buy-side)
Aug 2026 Supernus Pharmaceuticals ––MergerAnnounced–Pharma Morgan Lewis (sell-side)Cantor Fitzgerald (sell-side)Wells Fargo Securities (sell-side)Saul Ewing (sell-side)Jefferies (buy-side)Piper Sandler (buy-side)Goodwin (buy-side)Citi (buy-side)
Aug 2026 BWXT Medical business BWX TechnologiesNordic CapitalAsset salePending800.0Radiopharmaceuticals+2 Solomon Partners (sell-side)Stikeman Elliott (sell-side)Kirkland & Ellis (buy-side)McCarthy Tétrault (buy-side)
Aug 2026 global rights for MT-7117 (dersimelagon) Tanabe PharmaLEO PharmaAsset saleCompleted435.0Pharma+2 Evercore (sell-side)Latham & Watkins (buy-side)
Jul 2026 Neurimmune's royalty interest in AstraZeneca's cliramitug NeurimmuneRoyalty PharmaAsset saleAnnounced250.0Pharma+1 Goodwin (buy-side)
Jul 2026 Avere Therapeutics –Hansoh Pharmaceutical Group Co.StakeAnnounced–Biotech+2 Goodwin (buy-side)
Jul 2026 newly established entity holding Bayer's long-acting reversible contraceptives (LARC) business BayerApolloStakeAnnounced3,465.9Pharma Latham & Watkins (buy-side)Paul, Weiss (buy-side)
Jul 2026 iRenix Medical –Tarsus PharmaceuticalsAcquisitionAnnounced75.0Ophthalmology+2 Piper Sandler (sell-side)DLA Piper (sell-side)Gunderson Dettmer (buy-side)
Jul 2026 Crinetics Pharmaceuticals –Vertex PharmaceuticalsAcquisitionAnnounced10,000.0Biotech+2 Lazard (buy-side)J.P. Morgan (sell-side)Leerink Partners (sell-side)Paul, Weiss (sell-side)Morrison & Foerster (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Jul 2026 Lannett –AurobindoAcquisitionCompleted250.0Pharma+1 Raymond JamesSullivan & Cromwell (buy-side)
Jun 2026 Andone Pharmaceuticals –SteriMaxAcquisitionCompleted–Pharma+2 Bloom Burton & Co. (sell-side)Bourne Partners (buy-side)
Jun 2026 Theravance Biopharma –ZymeworksAcquisitionPending929.0Pharma+1 Lazard (sell-side)Evercore (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Arthur Cox (sell-side)Kirkland & Ellis (buy-side)Matheson (buy-side)MTS Health Partners (buy-side)
Jun 2026 Azora Therapeutics –Adial PharmaceuticalsAsset saleCompleted–Biotech+2 Lucid Capital Markets (sell-side)Honigman (sell-side)Oppenheimer & Co. (buy-side)Blank Rome (buy-side)
Jun 2026 US generic and specialty pharmaceutical product portfolio of Nordic Pharma Nordic PharmaJ. MolnerAsset saleCompleted–Pharma Raymond James
May 2026 Altruix WindRose Health InvestorsFrazier Healthcare PartnersAcquisitionCompleted–Behavioral Health+1 Houlihan Lokey (sell-side)Cantor Fitzgerald (sell-side)Latham & Watkins (sell-side)Goodwin (buy-side)
May 2026 Mentari Therapeutics –InMed PharmaceuticalsAcquisitionAnnounced–Biotech+1 Wedbush Securities (sell-side)Gibson Dunn (sell-side)Lucid Capital Markets (buy-side)Norton Rose Fulbright (buy-side)
May 2026 Exclusive development and commercialisation rights to Idefirix in Europe and MENA Hansa Biopharma ABSERB PharmaceuticalsAsset salePending133.6Pharma+1 Freshfields (buy-side)Mayer Brown (buy-side)
May 2026 Orphai Therapeutics –Quince TherapeuticsAcquisitionCompleted–Biotech+2 Cooley (sell-side)LifeSci Capital (buy-side)Dorsey & Whitney (buy-side)Oppenheimer & Co. (buy-side)Gibson Dunn (buy-side)
May 2026 Catalyst Pharmaceuticals –Angelini Pharma S.p.A.AcquisitionPending4,100.0Pharma+1 J.P. Morgan (sell-side)Kirkland & Ellis (sell-side)Akerman (sell-side)Centerview Partners (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Hogan Lovells Cadwalader (buy-side)Gatti Pavesi Bianchi Ludovici (buy-side)
May 2026 Esperion Therapeutics –ARCHIMEDAcquisitionPending1,100.0Pharma+1 Latham & WatkinsCenterview Partners (sell-side)Goodwin (sell-side)Moelis & Company (buy-side)Sidley Austin (buy-side)
May 2026 CVC and GBL-led Recordati acquisition consortium –CPP InvestmentsStakeAnnounced–Pharma Kirkland & Ellis (buy-side)
May 2026 Recordati S.p.A. –CVC GBLAcquisitionAnnounced12,516.9Pharma Latham & Watkins (buy-side)Jefferies (buy-side)
Apr 2026 KalVista Pharmaceuticals –Chiesi GroupAcquisitionCompleted1,900.0Pharma+2 Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Fenwick & West (sell-side)Jefferies (sell-side)Lazard (buy-side)Ropes & Gray (buy-side)
Apr 2026 Shionogi-Apnimed Sleep Science ApnimedShionogi & Co.AcquisitionAnnounced100.0Pharma+1 Goodwin (sell-side)
Apr 2026 Emalex Biosciences –Teva PharmaceuticalsAcquisitionAnnounced700.0Pharma+1 Centerview Partners (sell-side)Bradley Arant Boult Cummings (sell-side)Evercore (buy-side)Faegre Drinker Biddle & Reath (buy-side)
Apr 2026 Organon & Co. –Sun Pharmaceutical IndustriesAcquisitionAnnounced11,750.0Pharma Morgan Stanley (sell-side)Goldman Sachs (sell-side)Sullivan & Cromwell (sell-side)Cyril Amarchand Mangaldas (sell-side)J.P. Morgan (buy-side)Jefferies (buy-side)White & Case (buy-side)AZB & Partners (buy-side)
Apr 2026 Kashiv BioSciences –Amneal PharmaceuticalsAcquisitionCompleted375.0Biotech+2 J.P. Morgan (sell-side)Holland & Knight (sell-side)Goldman Sachs (buy-side)Richards, Layton & Finger (buy-side)Simpson Thacher & Bartlett (buy-side)Boston Consulting Group (buy-side)
Apr 2026 Cumberland FDA-approved commercial products and related assets Cumberland PharmaceuticalsNuvo Pharmaceuticals (Ireland) DACAsset salePending100.0Pharma VelocityHealth Securities (sell-side)Baker Donelson (sell-side)Kirkland & Ellis (buy-side)
Apr 2026 Neurona Therapeutics –UCBAcquisitionAnnounced650.0Biotech+2 Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side)
Apr 2026 US sales and distribution rights for seven Assertio branded products Assertio HoldingsCosette PharmaceuticalsAsset saleAnnounced–Pharma Gibson Dunn (sell-side)
Apr 2026 Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup) Assertio HoldingsCosette PharmaceuticalsAsset saleCompleted35.0Pharma Moelis & Company (sell-side)Gibson Dunn (sell-side)
Apr 2026 Worldwide rights to Kenalog Bristol-Myers SquibbSubsidiary of Piramal PharmaAsset saleAnnounced35.0Pharma Goodwin (buy-side)
Apr 2026 Assertio Holdings –Zydus Worldwide DMCCAcquisitionAnnounced166.4Pharma Moelis & Company (sell-side)Gibson Dunn (sell-side)Longacre Square Partners (sell-side)Paul, Weiss (buy-side)
Apr 2026 Soleno Therapeutics –Neurocrine BiosciencesAcquisitionCompleted2,900.0Biotech+2 Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side)
Apr 2026 Exclusive global rights to TAK-063 (balipodect) Takeda Pharmaceutical Co.Axsome TherapeuticsAsset saleCompleted–Pharma+1 Sidley Austin (buy-side)
Apr 2026 Cumberland U.S. branded businesses Cumberland PharmaceuticalsApotexAsset saleAnnounced–Pharma Kirkland & Ellis (buy-side)
Apr 2026 Modeyso commercial sales royalties Former Oncoceutics Inc. securityholdersHealthCare RoyaltyAsset saleAnnounced–Specialty finance and leasing+3 Latham & Watkins (sell-side)
Mar 2026 Apellis Pharmaceuticals –BiogenAcquisitionAnnounced5,600.0Biotech+2 Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side)
Mar 2026 Centessa Pharmaceuticals –Eli Lilly and CompanySchemePending6,300.0Biotech+1 Centerview Partners (sell-side)Jefferies (sell-side)Goodwin (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Mar 2026 Kezar Life Sciences –Aurinia PharmaceuticalsAcquisitionAnnounced51.5Biotech+1 TD Securities (sell-side)Cooley (sell-side)
Mar 2026 AnaptysBio outstanding common stock –AnaptysBioBuy-backAnnounced100.0Biotech+1 Piper Sandler (buy-side)
Mar 2026 AZSTARYS business Corium Therapeutics HoldingsCollegium PharmaceuticalAsset salePending650.0Pharma Centerview Partners (sell-side)Sullivan & Cromwell (sell-side)Leerink Partners (buy-side)Goodwin (buy-side)
Mar 2026 Day One Biopharmaceuticals –ServierAcquisitionPending2,500.0Biotech+2 Centerview Partners (sell-side)Fenwick & West (sell-side)Goldman Sachs (buy-side)Baker McKenzie (buy-side)Innisfree M&A (buy-side)

Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.